Myelodysplastic Syndrome Drugs Market by Therapeutic Classes (Hypomethylating Agents, Immunomodulatory Drugs, and Anti-anemics), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global myelodysplastic syndrome drugs market size is expected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising presence of novel therapeutics, improving healthcare services, and growing geriatric population.
 

Myelodysplastic syndrome (MDS) is caused due to mutation of one or more genes which control the blood cells development. It is a common type of malignant hematological diseases. Every year it is affecting around five out of every 100,000 people in the US. Around 60,000 people live with MDS in the U.S. and every year around 12,000-15,000 new cases are getting reported. Patients are present with clinical manifestations including anemia, thrombocytopenia, and neutropenia. There are some factors such as heavy metals (including mercury and lead) and exposure to chemicals (includes pesticides, tobacco, and benzene) are activating the disease onset.

Currently, demand of hypomethylating agents is rising because of approval and adoption of Vidaza and Dacogen. Huge pipeline including Aranesp is anticipated to aid the market in the coming years. Easy accessibility and availability of new treatments in developed countries gives opportunity to the market. The non-profit health organization such as MDS International Foundation support psychologically along with funding for the treatment of the patients.

Globally, increase in geriatric population as MDS is generally found in this population due to which disease remains incurable. Therefore, substantial progress is made in MDS diagnosis by using sequencing technologies. Using this technology chromosomal abnormalities in MDS patients are identified. Available therapies are efficacious, but commonly they are not curative. Due to high cost of therapeutics, several affordable healthcare measures were implemented across all key markets and affecting major market players. Currently, stem cell transplant is the only cure for myelodysplastic syndrome. But, it includes high risk and patients with medical complications are not eligible.

Market Trends, Drivers, Restraints, and Opportunities

• Growing prevalence of myelodysplastic syndrome and rising geriatric population are projected to drive the growth of the market over the forecast period.
• Favorable government initiatives is expected to push the growth of the market over the forecast period.
• Rising incidence of niche indications and improvement in healthcare services are anticipated to fuel the expansion of the market.
• Increasing awareness about disease among people and easy reimbursement policies are estimated to boost the market expansion in the coming years.
• Rising development of novel therapeutics is one of the major factor propelling the market expansion in the coming years.
• High cost of drugs and several side effects are major factor responsible for hampering the market growth over the forecast period.

Scope of the Report

The report on the global myelodysplastic syndrome drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Immunomodulatory drugs segment is projected to hold a major market share
Based on therapeutic classes, the myelodysplastic syndrome drugs market is divided into hypomethylating agents, immunomodulatory drugs, and anti-anemics. The immunomodulatory drugs segment is expected to hold a key share of the market during the forecast period owing to lack of generic competition and increasing adoption of therapeutics. Only one approved treatment for low-risk MDS is Revlimid (lenalidomide).

On the other hand, the hypomethylating agents segment is anticipated to expand at a rapid pace during the forecast period. Hypomethylating agents includes Celgene’s Vidaza and Otsuka’s Dacogen, which are used as a first line of treatment for high-risk patients. Also, anti-anemics drug segment is increasing at significant pace. Celgene’s luspatercept and Amgen’s Aranesp are under investigation in clinical trials of treatments. Usage of anti-anemics drug aids rising RBC count in the blood, hence decreases the requirement of frequent blood transfusions.
 

North America is expected to dominate the market
On the basis of regions, the myelodysplastic syndrome drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to multiple product launches in the region. Moreover, rising adoption of novel therapies, high cost of treatment, and presence of a large cohort in the U.S. are expected to fuel the regional market growth.
 

Segments

Segments Covered in the Report
The global myelodysplastic syndrome drugs market has been segmented on the basis of

Therapeutic classes

• Hypomethylating Agents
• Immunomodulatory Drugs
• Anti-anemics

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Celgene
• Amgen
• Otsuka
• Mylan N.V.
• Pfizer, Inc.
• Takeda
• AbbVie
• Dr. Reddy's Laboratories
• Accord Healthcare
• Bristol-Myers Squibb
• Sandoz, Inc.
• Novartis AG

Competitive Landscape

Key players competing in the myelodysplastic syndrome drugs market include Celgene; Amgen; Otsuka; Mylan N.V.; Pfizer, Inc.; Takeda; AbbVie; Dr. Reddy's Laboratories; Accord Healthcare; Bristol-Myers Squibb; Sandoz, Inc.; and Novartis AG. Major market player are adopting several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.